The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.
This JMCP article assesses the ability of the BBCIC distributed research network to serve as a potential resource for surveillance of biologics. The study provides recommendations to improve future comparative safety and effectiveness studies of biologics.
For two drugs with a branded product that had a large price increase, the market share of the related biosimilar or generic was higher among Medicaid MCOs not subject to preferred drug lists (PDLs) as compared to MCOs subject to PDLs and Medicaid FFS programs, according to a JMCP study.